GlassScriptPhysician profile
Bohan Xing
NPI 1891319042
$3,231.60
in general payments reported to CMS, 2019-2025
12 companies · $576 in 2025
The $576 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $673 · 2023: $1,476 · 2024: $393 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.00 |
| Education | $109.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $836.94 | 2022-2025 | Clareon, Tryptyr, Acrysof Toric Aspheric Uv Absorbing Iol |
| Johnson & Johnson Surgical Vision, INC. | $682.11 | 2023 | Lipiflow System Activator (Disposable), Lipiflow System Activator II (Disposable, Meibomian Gland Evaluator |
| Glaukos Corporation | $518.80 | 2022-2024 | Istent Trabecular Micro-Bypass System Model Is3, Istent Inject Trabecular Micro-Bypass System, Istent Infinite Trabecular Micro Bypass System |
| Mallinckrodt Hospital Products INC. | $425.69 | 2025 | Acthar |
| Bausch & Lomb Americas INC. | $135.61 | 2023-2024 | Envista Mx60 Iol, Stellaris |
| Rxsight INC | $134.40 | 2022 | |
| Amgen INC. | $125.00 | 2024 | Tepezza |
| Dompe US, INC. | $124.98 | 2022 | |
| Abbvie INC. | $114.68 | 2023 | Durysta |
| Allergan, INC. | $99.99 | 2021 | |
| Carl Zeiss Meditec Cataract Technology INC. | $19.56 | 2022 | |
| Sight Sciences, INC. | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bohan Xing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.